Publication: Evaluation of the hemavision-28q fusion transcript for acute leukemia screening panel
No Thumbnail Available
Date
2025-01
Authors
Tarannum, Nowshin
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Acute leukemia is a hematopoietic cell malignancy characterized by excessive proliferation of immature blood cells, resulting in severe disruption of normal hematopoiesis. The accurate and timely discovery of genetic abnormalities, particularly chromosomal translocations, is crucial for effective acute leukemia diagnosis, prognosis, and therapy planning. This study compares the performance of the HemaVision-28Q kit, a real-time quantitative PCR (RT-qPCR)-based assay, to the HemaVision-28N assay, which uses nested PCR to detect fusion gene transcripts associated with acute leukemia. The goal was to evaluate HemaVision-28Q's sensitivity, specificity, and clinical value as a diagnostic tool, as well as its capacity to detect both positive and negative fusion transcript cases. Archived RNA samples from the peripheral blood and bone marrow of acute leukemia patients were examined using the HemaVision-28Q and HemaVision-28N assays. The HemaVision-28Q performed admirably, detecting 28 clinically important fusion gene transcripts quickly and consistently, including t(9;22) [BCR-ABL1], t(15;17) [PML-RARA], and inv(16) [CBFB-MYH11]. The assay was found to be highly sensitive and specific, with a faster turnaround time than HemaVision-28N. Its workflow reduced the need for labor-intensive stages such as gel electrophoresis, lowering the danger of contamination and making it an affordable and viable option for regular clinical diagnostics. In contrast, the HemaVision-28N assay, which provided thorough exon-level analysis of fusion genes, was time-consuming and required more technical knowledge. The study's findings emphasize the HemaVision-28Q kit as a dependable diagnostic option for acute leukemia, especially in clinical settings where speed and efficiency are critical
Description
Keywords
-